influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models非核苷逆转录酶抑制剂的影响(依法韦伦和奈韦拉平)的药效学活性格列齐特在动物模型.pdfVIP

下载本文档

1
0
约5.62万字
约 8页
2017-09-11 发布于上海
举报
版权申诉

influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models非核苷逆转录酶抑制剂的影响(依法韦伦和奈韦拉平)的药效学活性格列齐特在动物模型.pdf

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models非核苷逆转录酶抑制剂的影响(依法韦伦和奈韦拉平)的药效学活性格列齐特在动物模型

Diabetology Metabolic Syndrome BioMed Central Research Open Access Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models SK Mastan*1,2 and K Eswar Kumar 1 Address: 1Pharmacology Division, AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam-530 003, Andhra Pradesh, India and 2Department of Pharmacology, Vignan Institute of Pharmaceutical Technology, Duvvada, Gajuwaka, Visakhapatnam-530 046, Andhra Pradesh, India Email: SK Mastan* - shkmastan@; K Eswar Kumar - ekilari@ * Corresponding author Published: 9 October 2009 Received: 1 July 2009 Accepted: 9 October 2009 Diabetology Metabolic Syndrome 2009, 1:15 doi:10.1186/1758-5996-1-15 This article is available from: /content/1/1/15 © 2009 Mastan and Kumar; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Type 2 diabetes may occur as a result of HIV infection and/or its treatment. Gliclazide is a widely used drug for the treatment of type 2 diabetes. Efavirenz and nevirapine are widely used non-nucleoside reverse transcriptase inhibitors for the treatment of HIV infection. The role of Efavirenz and nevirapine on the pharmacodynamic activity of gliclazide